Linic.[1?] Previously, liquid-oil filled NPs had been developed to provide DX. Even so, in spite of the*John A. McNeill Distinguished Prof. R. J. Mumper, Corresponding Author, Center for Nanotechnology in Drug Delivery, Division of Molecular Pharmaceutics, UNC Eshelman College of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA, UNC Lineberger Extensive Cancer Center, University of North Carolina at Chapel Hill, NC, USA, CB# 7355, 100G Beard Hall, University of North Carolina at Chapel Hill, [email protected] et al.Pagedesirable formulation properties (e.g., monodisperse particle size, apparent drug entrapment efficiency, and so forth.), DX was discovered to become extremely swiftly released in mouse plasma in-vitro. To overcome the poor retention of DX within the oil-filled NPs in simple aqueous phase and in biologically relevant medium, DX was modified by attaching fatty acid chains with unique chain lengths to the 2′-position of DX through an ester bond.2,4-Dimethylpyrimidin-5-ol Price [4] The 3 DX-lipid conjugates synthesized within the prior research increased the drug solubility in oil phase by 10-fold. Consequently, the DX-lipid conjugates were well retained inside the NPs even in one hundred plasma. The retention of DX conjugates within the long-circulating NPs resulted in substantially decreased elimination and high and prolonged systemic drug exposure. However, in-vitro cytotoxicity research revealed that these DX conjugates were considerably much less potent than the unmodified DX.[4] Comparable results have been reported by other groups.[5] It has been lengthy recognized that the 2′-OH is important for the microtubule binding and cytotoxic effect of DX.[6] Hence, the biological activity of these ester prodrugs largely depends upon the liberation of active DX. The compromised cytotoxicity suggests inefficient release of DX in cell culture. The in-vitro hydrolysis and in-vivo pharmacokinetics also revealed sub-optimal hydrolysis kinetics of those conjugates.[4] Ali et al. synthesized a series of lipid paclitaxel (PX) prodrugs with or without the need of a bromine atom at the 2-position on the fatty acid chain.[7] In general, the prodrugs lacking bromine have been 50- to 250-fold significantly less active than their bromoacyl counterparts indicating that the electron-withdrawing group facilitated the cleavage of active PX. The bromoacylated PX showed larger anticancer efficacy against OVCAR-3 tumor in-vivo.[7,8] Their findings suggest that this rationale and facile modification has the potential to favorably modify the physicochemical and biological properties in the DX conjugates. The objective of those present studies was to further tune the prodrug hydrolysis kinetics whilst retaining the higher drug entrapment and retention inside the oil-filled NPs.105751-18-6 Purity With optimized activation kinetics, the new prodrug containing NPs were expected to achieve sustained release of active drug, low systemic toxicity, and enhanced antitumor efficacy in-vivo.PMID:24818938 NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript 2. Results2.1. Synthesis and characterization of 2-Br-C16-DX DX was modified for the far more lipophilic prodrug, 2-Br-C16-DX, by a one-step esterification reaction with a 2-bromohexadecanoyl chain attached for the 2′-position of DX (Figure 1). The 2′-OH is the most reactive hydroxyl group amongst the a number of hydroxyl groups in DX molecule, followed by 7-OH and 10-OH.[5] The presence of bromine on the acyl chain created the carboxylic acid much more reactive than its counterpart lack of bromine to ensure that along with 2′-substitution,.